home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Genomics used in drugtesting

 
  November, 7 2001 0:31
your information resource in human molecular genetics
 
     
ChemGenex uses genomics approach to develop new anticancer drug and predict possible side effects

Understanding how genes respond to chemicals in diseased and normal tissues, in both cell cultures and living systems, can help researchers develop new drugs more efficiently. Such knowledge can spotlight drug toxicities, help select dosing regimens for clinical trials, and identify which patients may best benefit from treatment. Researchers from ChemGenex present data showing the use of chemical genomics and informatics in the development of a new cancer therapeutic, now in Phase I/II human testing.

ChemGenex Therapeutics

Contact:
Joan Kureczka
JKureczka@aol.com
415-821-2413
J. Kureczka Associates


Message posted by: Wouter Kalle

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.